Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Cytosorbents Corporation (CTSO) had Revenue of $9.48M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$9.48M
Net Income	$-3.17M
Cost of Goods Sold	$2.82M
Gross Profit	$6.67M
Operating Expenses	$12.35M
Operating Income	$-2.86M
Non-Operating Income/Expense	$-0.71M
Pre-Tax Income	$-3.57M
Normalized Pre-Tax Income	$-3.57M
Income after Taxes	$-3.17M
Income from Continuous Operations	$-3.17M
Consolidated Net Income/Loss	$-3.17M
Normalized Income after Taxes	$-3.17M
EBIT	$-2.86M
EBITDA	$-2.27M
Weighted-Average Shares Outstanding (Basic)	62.75M
Weighted-Average Shares Outstanding (Diluted)	62.75M
Earnings per Share (EPS) (Basic)	$-0.05
Earnings per Share (EPS) (Diluted)	$-0.05
Balance Sheet Financials
Current Assets	$21.31M
Property, Plant, and Equipment	$8.19M
Long-Term Assets	$24.44M
Total Assets	$45.75M
Current Liabilities	$10.11M
Long-Term Debt	$14.57M
Long-Term Liabilities	$26.62M
Total Liabilities	$36.73M
Common Equity	$9.02M
Tangible Shareholders Equity	$9.02M
Shareholders Equity	$9.02M
Common Shares Outstanding	62.79M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-7.55M
Cash Flow from Investing Activities	$-0.12M
Cash Flow from Financial Activities	$6.83M
Beginning Cash	$9.76M
End Cash	$9.06M
Increase/Decrease in Cash	$-0.71M
Stock-Based Compensation	$2.13M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.11
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.62
Debt to Equity Ratio	1.61
Gross Margin	70.28%
Operating Margin	-30.17%
EBIT Margin	-30.17%
EBITDA Margin	--
Pre-Tax Profit Margin	-37.65%
Profit Margin	-33.42%
Free Cash Flow	$-7.61M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.21
Inventory Turnover	0.70
Receiveable Turnover	1.28
Days Sales in Receivables	70.47
Return on Equity	-35.14%
Return on Tangible Equity	-35.14%
Return on Assets	-6.93%
Return on Investments	-13.44%
Book Value Per Share	$0.14
Free Cash Flow per Share	$-0.12
Operating Cash Flow per Share	$-0.12

Data from Zacks Investment Research, Inc.